Keapstone Therapeutics
Keapstone Therapeutics provides drug development and neurodegeneration services.
Keapstone Therapeutics operates in biotechnology, therapeutics based in Europe, Middle East, and Africa (EMEA), founded in 2017.
The company sits in the biotechnology, therapeutics segment, where it competes on its core product or service.
Europe, Middle East, and Africa (EMEA) is where the company is located.
Its current recorded stage is Seed.
Recorded headcount: c_00001_00010 employees.
Total disclosed funding stands at about $2.4M.
| Sector | Biotechnology, Therapeutics |
|---|---|
| Headquarters | Europe, Middle East, and Africa (EMEA) |
| Founded | 2017 |
| Employees | c_00001_00010 |
| Stage | seed |
| Total funding | $2,400,000 |
Website: www.keapstone.com
Contact details and direct channels are available to signed-in members.
Create a free account
Create a free account